{
    "tool": "clinical-trials",
    "count": 20,
    "results": [
        {
            "query": "semaglutide",
            "nctId": "NCT07295223",
            "title": "Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)",
            "officialTitle": "GLP-1 and Antidiabetic SGLT2 Agents for Myocardial Infarction and Ultrasensitive Inflammatory Surveillance: An Open-Label Pilot Study",
            "status": "COMPLETED",
            "phases": [
                "PHASE3"
            ],
            "studyType": "INTERVENTIONAL",
            "conditions": [
                "Acute Myocardial Infarction With ST Elevation"
            ],
            "interventions": [
                "DRUG: Dapagliflozin 10 MG Oral Tablet",
                "DRUG: Semaglutide (Rybelsus®)"
            ],
            "sponsor": "Instituto Mexicano del Seguro Social",
            "sponsorClass": "OTHER_GOV",
            "enrollment": 44,
            "startDate": "2025-12-30",
            "primaryCompletionDate": "2026-10-30",
            "lastUpdated": "2026-11-04",
            "hasResults": false,
            "locationCount": 1,
            "countries": [
                "Mexico"
            ],
            "sampleLocations": [
                "Hospital de Especialidades No.1, Centro Médico Nacional del Bajío, León, Guanajuato, Mexico"
            ],
            "briefSummary": "The primary risk factor for coronary artery disease is atherosclerosis, with inflammation playing a crucial role in the development and progression of this condition. It has now been proven that inflammation is key in the development of complications after an acute myocardial infarction. These complications can be immediate and mechanical, such as ventricular wall rupture and ventricular arrhythmia, or long-term, presenting as major cardiovascular events like heart failure.\n\nDuring acute myocardial infarction (AMI), circulating high-sensitivity CRP levels increase approximately 6 hours after the onset of ischemia. CRP levels measured between 24 and 72 hours after symptom onset are a significant prognostic marker for one-year outcomes. Higher high-sensitivity CRP levels at the time of AMI are linked to more severe coronary atherosclerotic lesions seen on angiography and lower LVEF one month after the event. A serum high-sensitivity CRP concentration greater than 10 mg/L after an AMI indicates inflammation, reflecting myocardial necrosis, plaque rupture, and acute thrombosis. In patients with AMI, persistent or increasing CRP levels are strongly associated with a higher risk of all-cause and non-cardiovascular death, especially when inflammation (CRP \\> 2.0 mg/L) continues for a year.\n\nAside from reperfusion therapy, very few pharmacological approaches have been used to reduce inflammation after AMI. One such approach was the use of colchicine in the COVERT-MI randomized, doubl",
            "url": "https://clinicaltrials.gov/study/NCT07295223"
        },
        {
            "query": "semaglutide",
            "nctId": "NCT07772960",
            "title": "Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes",
            "officialTitle": "Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes",
            "status": "RECRUITING",
            "phases": [
                "PHASE1"
            ],
            "studyType": "INTERVENTIONAL",
            "conditions": [
                "Alcohol Use Disorder (AUD)",
                "Obesity (BMI Equal to or >30)"
            ],
            "interventions": [
                "OTHER: Placebo",
                "DRUG: Semaglutide 1.0 mg",
                "DRUG: Semaglutide 2.0 mg"
            ],
            "sponsor": "Yale University",
            "sponsorClass": "OTHER",
            "enrollment": 90,
            "startDate": "2026-10-01",
            "primaryCompletionDate": "2031-10-31",
            "lastUpdated": "2026-11-04",
            "hasResults": false,
            "locationCount": 2,
            "countries": [
                "United States"
            ],
            "sampleLocations": [
                "Yale Stress Center, New Haven, Connecticut, United States",
                "Yale Stress Center, New Haven, Connecticut, United States"
            ],
            "briefSummary": "This study will examine two doses of 1.0 mg and 2.0 mg of Semaglutide versus placebo in patients with Alcohol Use Disorder (AUD) and Obesity (Ob) to assess if these doses improve alcohol craving, stress and alcohol use outcomes.",
            "url": "https://clinicaltrials.gov/study/NCT07772960"
        },
        {
            "query": "semaglutide",
            "nctId": "NCT06975111",
            "title": "Focusing on the Menopausal Transition to Improve Mid-Life Women's Health",
            "officialTitle": "Focusing on the Menopausal Transition to Improve Mid-Life Women's Health",
            "status": "RECRUITING",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "studyType": "INTERVENTIONAL",
            "conditions": [
                "Menopause",
                "Menopause Hot Flashes",
                "Menopause Related Conditions",
                "Cardiovascular"
            ],
            "interventions": [
                "DRUG: Metformin",
                "DRUG: semaglutide",
                "DRUG: Anti-hypertensives",
                "DRUG: Lipid Lowering Medication",
                "BEHAVIORAL: Life style intervention",
                "DRUG: Fezolinetant",
                "DRUG: Hormonal therapy"
            ],
            "sponsor": "University of Colorado, Denver",
            "sponsorClass": "OTHER",
            "enrollment": 200,
            "startDate": "2026-03-01",
            "primaryCompletionDate": "2029-10-31",
            "lastUpdated": "2026-11-04",
            "hasResults": false,
            "locationCount": 3,
            "countries": [
                "United States"
            ],
            "sampleLocations": [
                "University of Colorado-School of Medicine, Aurora, Colorado, United States",
                "University of North Carolina, School of Medicine, Chapel Hill, North Carolina, United States",
                "Virginia Commonwealth University, Richmond, Virginia, United States"
            ],
            "briefSummary": "What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce menopause-related inflammation, restore a healthier cardiometabolic profile, reverse epigenetic aging, and reduce bothersome menopausal symptoms? The ultimate goal of this work is to attenuate future disease and enhance women's quality of life, extend healthspan and increase productivity.",
            "url": "https://clinicaltrials.gov/study/NCT06975111"
        },
        {
            "query": "semaglutide",
            "nctId": "NCT06897475",
            "title": "A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide",
            "officialTitle": "A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c Goal",
            "status": "RECRUITING",
            "phases": [
                "PHASE2"
            ],
            "studyType": "INTERVENTIONAL",
            "conditions": [
                "Type 2 Diabetes"
            ],
            "interventions": [
                "DRUG: LY3457263",
                "DRUG: Placebo"
            ],
            "sponsor": "Eli Lilly and Company",
            "sponsorClass": "INDUSTRY",
            "enrollment": 200,
            "startDate": "2025-03-28",
            "primaryCompletionDate": "2027-05",
            "lastUpdated": "2026-11-04",
            "hasResults": false,
            "locationCount": 60,
            "countries": [
                "United States",
                "Canada",
                "Germany",
                "Poland",
                "Puerto Rico",
                "United Kingdom"
            ],
            "sampleLocations": [
                "Helios Clinical Research - Phoenix, Phoenix, Arizona, United States",
                "Wolverine Clinical Trials, Santa Ana, California, United States",
                "Renstar Medical Research, Ocala, Florida, United States",
                "Oviedo Medical Research, Oviedo, Florida, United States",
                "Balanced Life Health Care Solutions/SKYCRNG, Lawrenceville, Georgia, United States"
            ],
            "briefSummary": "The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.",
            "url": "https://clinicaltrials.gov/study/NCT06897475"
        },
        {
            "query": "semaglutide",
            "nctId": "NCT07832084"
        }
    ],
    "_note": "Response truncated for documentation purposes"
}